[go: up one dir, main page]

WO2002028353A3 - Inhibiteur du transport de phosphate - Google Patents

Inhibiteur du transport de phosphate Download PDF

Info

Publication number
WO2002028353A3
WO2002028353A3 PCT/US2001/031318 US0131318W WO0228353A3 WO 2002028353 A3 WO2002028353 A3 WO 2002028353A3 US 0131318 W US0131318 W US 0131318W WO 0228353 A3 WO0228353 A3 WO 0228353A3
Authority
WO
WIPO (PCT)
Prior art keywords
transport inhibitors
phosphate transport
phosphate
useful
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031318
Other languages
English (en)
Other versions
WO2002028353A2 (fr
Inventor
Joseph Weinstock
Robert G Franz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2002213048A priority Critical patent/AU2002213048A1/en
Publication of WO2002028353A2 publication Critical patent/WO2002028353A2/fr
Publication of WO2002028353A3 publication Critical patent/WO2002028353A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de thiophène qui sont utiles pour traiter l'insuffisance rénale chronique et la maladie urémique osseuse.
PCT/US2001/031318 2000-10-05 2001-10-05 Inhibiteur du transport de phosphate Ceased WO2002028353A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213048A AU2002213048A1 (en) 2000-10-05 2001-10-05 Phosphate transport inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23806800P 2000-10-05 2000-10-05
US60/238,068 2000-10-05

Publications (2)

Publication Number Publication Date
WO2002028353A2 WO2002028353A2 (fr) 2002-04-11
WO2002028353A3 true WO2002028353A3 (fr) 2002-07-11

Family

ID=22896359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031318 Ceased WO2002028353A2 (fr) 2000-10-05 2001-10-05 Inhibiteur du transport de phosphate

Country Status (2)

Country Link
AU (1) AU2002213048A1 (fr)
WO (1) WO2002028353A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149527B2 (en) 2010-06-07 2015-10-06 Novomedix, Llc Furanyl compounds and the use thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830431A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002100851A2 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et procedes destines au traitement des infections par flavivirus
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
MXPA04004837A (es) * 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
ES2346961T3 (es) 2001-11-22 2010-10-22 Biovitrum Ab Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
CA2515780C (fr) * 2003-02-20 2012-12-11 Encysive Pharmaceuticals Inc. Antagonistes du recepteur de l'urotensine-ii de la phenylenediamine et antagonistes du ccr-9
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
SG161315A1 (en) 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JPWO2008026687A1 (ja) 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
EP2207772A1 (fr) * 2007-10-05 2010-07-21 Encysive Pharmaceuticals, Inc. Modulateurs de récepteur ccr9 et leurs procédés d'utilisation
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
EP2384318B1 (fr) 2008-12-31 2017-11-15 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
AU2010242307A1 (en) * 2009-04-30 2011-11-24 Sumitomo Chemical Company, Limited Thiophene derivative
MX342521B (es) * 2011-10-27 2016-10-03 Astellas Pharma Inc Derivado de n-tienilbenzamida sustituido con aminoalquilo.
HK1211469A1 (en) 2012-08-21 2016-05-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014250956B2 (en) 2013-04-12 2019-04-04 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
WO2018129557A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibiteurs d'antiport à médiation par nhe
WO2018129552A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés utiles pour le traitement de troubles du tractus digestif
WO2019167863A1 (fr) 2018-02-27 2019-09-06 日本曹達株式会社 Composé de sulfonamide hétéroaryle et agent de lutte antiparasitaire
WO2022193187A1 (fr) * 2021-03-17 2022-09-22 Biofront Ltd. (Cayman) Modulateurs de fpr1 et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421365A2 (fr) * 1989-10-03 1991-04-10 Wakamoto Pharmaceutical Co., Ltd. Dérivés d'acide tétrazolacétique ayant une activité inhibitrice de l'aldose-réductase
WO2000002851A1 (fr) * 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh N-arylamides d'acide sulfonylaminocarboxylique a substitution soufre, preparation et utilisation de ces derniers, preparations pharmaceutiques contenant ces composes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421365A2 (fr) * 1989-10-03 1991-04-10 Wakamoto Pharmaceutical Co., Ltd. Dérivés d'acide tétrazolacétique ayant une activité inhibitrice de l'aldose-réductase
WO2000002851A1 (fr) * 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh N-arylamides d'acide sulfonylaminocarboxylique a substitution soufre, preparation et utilisation de ces derniers, preparations pharmaceutiques contenant ces composes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149527B2 (en) 2010-06-07 2015-10-06 Novomedix, Llc Furanyl compounds and the use thereof

Also Published As

Publication number Publication date
WO2002028353A2 (fr) 2002-04-11
AU2002213048A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
WO2002028353A3 (fr) Inhibiteur du transport de phosphate
NZ516619A (en) Phosphate transport inhibitors
AU2003300779A1 (en) Catheter system for renal therapy
AU2001284483A1 (en) Remedies for heart failure
ZA200110479B (en) Respiratory syncytial virus replication inhibitors.
ZA200110473B (en) Respiratory syncytial virus replication inhibitors.
AU7842500A (en) System for orthopedic treatment
WO2001068096A3 (fr) Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
AU2001276344A1 (en) System for removing body fluid, especially blood
AU2001234088A1 (en) TNF-alpha inhibitors
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU773240C (en) Medicament for treating hypertension
BR0110034A (pt) Inibidores do transporte de fosfatos
AU2002216765A1 (en) Block boot for railway track systems
AU2001239510A1 (en) Treatment of renal disorders
WO2002056876A3 (fr) Traitement pour le ronflement
AU2001232245A1 (en) Tnf- alpha inhibitors
AUPQ232599A0 (en) Drug for treating fractures
WO2001060343A3 (fr) Utilisation d'acide 2-methyl-thiazolidin-2,4-dicarboxylique (2-mtdc) et/ou de ses sels physiologiquement compabibles pour le traitement et/ou la prevention de cancers
AU2001232053A1 (en) System for the extracorporeal treatment of blood
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
AU6328700A (en) Method for immobilising physiologically active compounds
AU2001274601A1 (en) Preventives or remedies for heart failure
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP